What Does Accuray (ARAY) Do? - Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters Summary
Accuray (ARAY) is a medical device company that operates a precision radiation therapy equipment and services business. Key items to monitor for the stock outlook include the revenue stream driven by CyberKnife and Radixact, the healthcare-provider investment environment, and the potential for a profitability recovery.
Subscribe🏢 What kind of company is Accuray?
Accuray (ARAY) is a US-headquartered radiation therapy solutions company. It provides equipment used in the treatment of tumors and neurological conditions, along with treatment planning software, data management capabilities, and installation, training, and post-installation support, helping healthcare providers run their treatment operations.
Its core business is precision radiation therapy delivered through CyberKnife and TomoTherapy-based Radixact systems. Beyond the treatment delivery equipment, the business is built around features that account for patient positioning and tumor motion, software that supports treatment planning and operations, and post-installation services.
💰 How does Accuray make money?
| Business Segment | Revenue Share | Description |
|---|---|---|
| Treatment Systems | Core revenue driver | Radiation therapy equipment based on CyberKnife and Radixact. |
| Services | Stabilizer | Installation, training, post-warranty support, and specialized services. |
Treatment system sales are influenced by healthcare providers' equipment purchase decisions and installation timelines, so quarterly trends can vary. By contrast, post-installation warranty, training, maintenance, and specialized services act as a recurring revenue stream built on the installed base. Software and adaptive therapy capabilities are supplementary elements that broaden the clinical utility of the equipment. Because product sales and service revenue move together, it is necessary to separate new orders, equipment shipments, and service demand from the installed base when reviewing performance.
📐 Accuray market cap and company scale
The market cap is $29.0M and the number of employees has not been disclosed.
Accuray operates within the medical device industry with a focus on radiation therapy delivery equipment and related services. Unlike broad-line medical device companies with wide product portfolios, it is characterized by its concentration in a specific treatment area. While service revenue can partially cushion the volatility of equipment sales, hospital capital investment and the pace of order conversion can have a significant impact on performance.
📈 Accuray outlook and stock trend
1-Year Price Performance
Analyst Consensus
52-Week Price RangeIn the short term, healthcare providers' equipment investment decisions, product shipment schedules, the regional sales mix, and existing orders can influence revenue and profitability. Over the medium to long term, expanding demand for precision radiation therapy, the use of AI-based adaptive treatment capabilities, and service demand from the installed base can serve as growth drivers. However, supply chain costs, FX, external policy factors such as tariffs, regulatory approval delays, adoption of competing products, debt burden, and the pace at which orders convert into revenue are volatility factors.
⚔️ Accuray key competitive strengths and risks
Its combination of precision treatment equipment and services is a strength, while healthcare-provider investment cycles, order conversion volatility, and financial burden are key risks.
💪 Key Competitive Strengths
⚠️ Key Risks
🔄 Accuray competitors and related (beneficiary) stocks
No listed companies were confirmed in the provided candidate group whose radiation therapy equipment, product lineup, and customer base clearly overlap with Accuray's. Therefore, the direct competitor and related stock list has been left empty. When a comparison is needed, it is appropriate to first examine healthcare providers' capital investment trends, adoption of radiation therapy, the stability of service revenue, and the pace at which orders translate into actual revenue.
| Ticker | Market Cap | PER | PBR | ROE | Dividend Yield | Change |
|---|---|---|---|---|---|---|
 ARAY | $29.0M | - | 0.7 | -80.08% | - | -2.8% |
| LLY | $1.06T | 38.2 | 31.2 | 102.43% | 0.61% | -0.1% |
| JNJ | $641.9B | 30.9 | 7.5 | 25.74% | 2.02% | -0.3% |
| ABBV | $450.6B | 72.1 | - | 15221.82% | 2.69% | +1.6% |
| MRK | $357.0B | 115.7 | 8.5 | 6.98% | 2.36% | -1.9% |
| UNH | $348.5B | 25.0 | 3.6 | 14.62% | 2.33% | -1.2% |
| Industry avg | - | 25.5 | 2.7 | -48.42% | 1.27% | - |
✅ Accuray investor checkpoints
When reviewing Accuray, it is important not to look at equipment sales alone, but to also examine the sustainability of service revenue, the process by which existing orders convert into revenue, and the healthcare-provider environment for treatment equipment investment. Whether the broader clinical use of precision treatment capabilities translates into actual demand is also a key observation item.
| Checkpoint | What to Verify | Current Status |
|---|---|---|
| 📈 Order Conversion | Review the flow of new orders, equipment shipments, and the conversion of the existing order backlog into revenue. | Conversion pace needs to be confirmed |
| 🩺 Service Trend | Check whether maintenance and specialized service demand from the installed base continues steadily. | Recurring revenue under observation |
| 💵 Financial Burden | Examine interest expenses, debt covenants, and any improvement in cash flow together. | Financial management review needed |
Because Accuray has a significant share of equipment sales, its performance can be sensitive to delays in hospital investment or changes in shipment schedules. The regional sales mix and product mix can shift margin trends, and supply chain costs, FX, regulatory approvals, competing equipment adoption, and debt-related costs are risk factors that should also be examined.
Accuray has a business structure that combines precision radiation therapy equipment with post-installation services. In future reviews, it is necessary to check the balance between equipment orders and service revenue, improvements in profitability, and any easing of financial burden together, and further verification is needed as a basis for individual judgments.
Subscribe Today's 5 AI picks, all free